Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22
|
作者：
Gay, Francesca [1 ]
Cerrato, Chiara [1 ]
Scalabrini, Delia Rota [1 ]
Galli, Monica [1 ]
Belotti, Angelo [1 ]
Zamagni, Elena [1 ]
Ledda, Antonio [1 ]
Grasso, Mariella [1 ]
Angelucci, Emanuele [1 ]
Liberati, Anna Marina [1 ]
Tosi, Patrizia [1 ]
Pisani, Francesco [1 ]
Spada, Stefano [1 ]
Annibali, Ombretta [1 ]
Baraldi, Anna [1 ]
Omede, Paola [1 ]
Galieni, Piero [1 ]
Rizzi, Rita [1 ]
Pescosta, Norbert [1 ]
Ronconi, Sonia [1 ]
Vincelli, Donatella [1 ]
Cafro, Anna Maria [1 ]
Offidani, Massimo [1 ]
Palumbo, Antonio [2 ,3 ]
Musto, Pellegrino [1 ]
Cavo, Michele [1 ]
Boccadoro, Mario [1 ]
机构：
[1] European Myeloma Network, GIMEMA, Milan, Italy
[2] Univ Torino, Turin, Italy
[3] Takeda Pharmaceut Co, Zurich, Switzerland
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-112093
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
121
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
    Gay, Francesca Maria
    Scalabrini, Delia Rota
    Belotti, Angelo
    Offidani, Massimo
    Petrucci, Maria Teresa
    Esma, Fabrizio
    Palmas, Angelo D.
    Caravita, Tommaso
    Grasso, Mariella
    Aquino, Sara
    Gamberi, Barbara
    Zambello, Renato
    Ledda, Antonio
    Montefusco, Vittorio
    Omede, Paola
    Galli, Monica
    Cavo, Michele
    Palumbo, Antonio
    Musto, Pellegrino
    Boccadoro, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Gay, F.
    Scalabrini, D. Rota
    Belotti, A.
    Offidani, M.
    Tacchetti, P.
    Petrucci, M. T.
    Pautasso, C.
    Palmas, A. D.
    Siniscalchi, A.
    Grasso, M.
    Spadano, A.
    Giuliani, N.
    Ballanti, S.
    Patriarca, F.
    Canepa, L.
    Bernardini, A.
    Aquino, S.
    Gamberi, B.
    Zambello, R.
    Ledda, A.
    Montefusco, V.
    Omede, P.
    Galli, M.
    Cavo, M.
    Palumbo, A.
    Musto, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 143 - 144
  • [3] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Derkach, Andriy
    Nemirovsky, David
    Ciardiello, Amanda
    Diamond, Benjamin
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Maclachlan, Kylee
    Patel, Dhwani
    Lahoud, Oscar B. B.
    Landau, Heather J. J.
    Chung, David J. J.
    Shah, Gunjan L. L.
    Scordo, Michael
    Giralt, Sergio A. A.
    Lesokhin, Alexander
    Usmani, Saad Z. Z.
    Landgren, Ola
    Korde, Neha
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [4] Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Carlyn Rose Tan
    Andriy Derkach
    David Nemirovsky
    Amanda Ciardiello
    Benjamin Diamond
    Malin Hultcrantz
    Hani Hassoun
    Sham Mailankody
    Urvi Shah
    Kylee Maclachlan
    Dhwani Patel
    Oscar B. Lahoud
    Heather J. Landau
    David J. Chung
    Gunjan L. Shah
    Michael Scordo
    Sergio A. Giralt
    Alexander Lesokhin
    Saad Z. Usmani
    Ola Landgren
    Neha Korde
    Blood Cancer Journal, 13
  • [5] CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)
    Popat, Rakesh
    Wilson, William
    Camilleri, Marquita
    De Tute, Ruth
    Pang, Gavin
    Jenner, Richard
    Dadaga, Tushhar
    Kamora, Sumaiya
    Streetly, Matthew
    Ramasamy, Karthik
    Phillips, Elizabeth
    Chapman, Mike
    Bygrave, Ceri
    Cavenagh, James
    Sive, Jonathan
    Benjamin, Reuben
    Eccersley, Lydia
    Hassan, Sandra
    Willis, Fenella
    Clifton-Hadley, Laura
    Owen, Roger
    Yong, Kwee
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S2 - S3
  • [6] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd M.
    Griffith, Kent
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Berdeja, Jesus G.
    Vij, Ravi
    Raje, Noopur
    Reece, Donna E.
    Vesole, David H.
    Jagannath, Sundar
    Kaminski, Mark
    Cole, Craig
    Nam, Jennifer
    Stephens, Leonor A.
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Dytfeld, Dominik
    Jakubowiak, Andrzej J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
  • [7] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [8] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    BLOOD, 2023, 142
  • [9] CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA PATIENTS: SUBGROUP ANALYSIS IN THE FORTE TRIAL
    Gay, F.
    Cerrato, C.
    Petrucci, M. T.
    Zambello, R.
    Rivolti, E.
    Ballanti, S.
    Omede, P.
    Gentile, M.
    Bernardini, A.
    Narni, F.
    Capra, A.
    De Sabbata, G.
    Gozzetti, A.
    Galieni, P.
    Rizzi, R.
    Pescosta, N.
    Cea, M.
    Molica, S.
    Cafro, A.
    Musolino, C.
    Spadano, A.
    Montefusco, V.
    Musto, P.
    Cavo, M.
    Boccadoro, M.
    HAEMATOLOGICA, 2019, 104 : 2 - 3
  • [10] Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study
    Knop, S.
    Kull, M.
    Kroenke, J.
    Drewniok, P.
    Schaefer-Eckart, K.
    von, Metzler I.
    Wolleschak, D.
    Kimmig, C.
    Greiner, J.
    Boettcher, S.
    Dechow, T.
    Hentrich, M.
    Khandanpour, C.
    Shumilov, E.
    Naumann, R.
    Seggewiss-Bernhardt, R.
    Hackanson, B.
    Wang, S. -Y.
    Salwender, H.
    Sormann, S.
    Stuebig, T.
    Brueggemann, M.
    Einsele, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 59
12345